Skip to content

Pascal Sienaert

2 papers in the library · 466 citations · publishing 2015-2026

Papers

Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study

Biological Psychiatry November 4, 2015 Jaskaran B. Singh, Maggie Fedgchin, Ella Daly et al. 466 citations

A single 40-minute intravenous infusion of esketamine at either 0.20 mg/kg or 0.40 mg/kg produced a rapid and robust antidepressant effect in patients with treatment-resistant depression, with significant improvement in depression scores within two hours. The higher and lower doses were similarly effective, but the lower dose may offer better tolerability. Common side effects included headache, nausea, and transient dissociation that resolved within four hours.

Sustained mood improvement with laughing gas exposure (SMILE): a randomised, placebo-controlled pilot trial of nitrous oxide for treatment-resistant depression: commentary, Kalmar et al

BJPsych Open July 1, 2026 Alain F. Kalmar, Pascal Sienaert, Filip Bouckaert et al.

Nitrous oxide, a potent greenhouse gas, is being explored as a treatment for therapy-resistant depression, but its environmental costs are often ignored. A single one-hour treatment produces about 150 kilograms of CO2-equivalents, and a year of treatment for one patient generates roughly 7.8 metric tons of CO2-equivalents. The authors argue that these environmental externalities should be factored into assessments of the therapy's overall value.